文献速递前列腺癌

外照射放疗联合近距离放疗与根治性前列腺切除联合辅助放疗治疗Gleason 9-10前列腺癌的比较

Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
PubMed 文献 · J Urol · 2019-10-09

比较外照射放疗联合近距离放疗与根治性前列腺切除联合辅助放疗治疗Gleason 9-10前列腺癌的总生存和前列腺癌特异性死亡。基于NCDB和SEER两个大型国家数据库,分别纳入4367例和2276例患者,采用逆概率治疗加权多变量Cox回归分析。结果显示两种治疗方式在5年总生存和前列腺癌特异性死亡率上均无显著差异。

要点

  • 在NCDB队列中,根治性前列腺切除联合辅助放疗与外照射放疗联合近距离放疗的5年总生存无显著差异(86.7% vs 87.0%,AHR 1.10,95% CI 0.95-1.27,p=0.220)。
  • 在SEER队列中,两种治疗方式的5年前列腺癌特异性死亡率无差异(6.0% vs 5.7%,AHR 1.22,95% CI 0.88-1.71,p=0.234)。
  • 患者年龄(65岁及以上 vs 小于65岁)与治疗方式之间在NCDB或SEER队列中均无显著交互作用。

核心结论

  • 在Gleason 9-10前列腺癌男性中,多模式手术治疗(根治性前列腺切除联合辅助放疗)与外照射放疗联合近距离放疗等效。

研究设计与样本

  • 使用NCDB和SEER两个大型国家数据库,分别识别4367例和2276例临床T1-T3N0M0、Gleason 9-10、前列腺特异性抗原0至40 ng/ml的前列腺癌患者,接受外照射放疗联合近距离放疗或根治性前列腺切除联合辅助放疗。
  • 采用逆概率治疗加权多变量Cox比例风险回归模型比较总生存和前列腺癌特异性死亡,并校正临床和人口学因素。

主要发现

  • NCDB队列中位随访6.0年,SEER队列中位随访5.8年。
  • NCDB队列中,根治性前列腺切除联合辅助放疗与外照射放疗联合近距离放疗的5年总生存无显著差异(86.7% vs 87.0%,AHR 1.10,95% CI 0.95-1.27,p=0.220)。
  • 仅纳入接受雄激素剥夺治疗的患者时,NCDB结果不变。
  • SEER队列中,两种治疗方式的5年前列腺癌特异性死亡率无差异(6.0% vs 5.7%,AHR 1.22,95% CI 0.88-1.71,p=0.234)。
  • 患者年龄(65岁及以上 vs 小于65岁)与治疗方式在NCDB或SEER队列中均无显著交互作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It remains controversial whether external beam radiation therapy with a brachytherapy boost provides oncologic outcomes equivalent to those of radical prostatectomy with or without adjuvant radiation therapy in men with Gleason 9-10 prostate cancer. We compared external beam radiation therapy plus brachytherapy to radical prostatectomy plus adjuvant radiation therapy for Gleason 9-10 prostate cancer in terms of overall survival and prostate cancer specific mortality in 2 large national databases. MATERIALS AND METHODS: Using the NCDB (National Cancer Database) and the SEER (Surveillance, Epidemiology, and End Results) database, we identified 4,367 and 2,276 patients, respectively, diagnosed with clinical T1-T3N0M0, Gleason 9-10, prostate specific antigen 0 to 40 ng/ml prostate cancer treated with external beam radiation therapy plus brachytherapy or radical prostatectomy plus adjuvant radiation therapy. We compared overall survival and prostate cancer specific mortality using inverse probability of treatment weighted multivariable Cox proportional hazards regression modeling after accounting for clinical and demographic factors. RESULTS: Median followup in the NCDB and SEER cohorts was 6.0 years and 5.8 years, respectively. In the NCDB cohort there was no significant difference in 5-year overall survival between radical prostatectomy plus adjuvant radiation therapy vs external beam radiation therapy plus brachytherapy (86.7% vs 87.0%, AHR 1.10, 95% CI 0.95-1.27, p=0.220). Results were unchanged when including only patients who received androgen deprivation therapy. In the SEER cohort there was no difference in 5-year prostate cancer specific mortality (6.0% vs 5.7%, AHR 1.22, 95% CI 0.0.88-1.71, p=0.234). There was no significant interaction between patient age (65 years or greater vs less than 65) and treatment modality in the NCDB or SEER cohorts. CONCLUSIONS: In men with Gleason 9-10 prostate cancer multimodality surgical therapy is equivalent to external beam radiation therapy plus brachytherapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Muralidhar V, Mahal BA, Butler S, et al. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019. PMID: 31144590. doi:10.1097/JU.0000000000000352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。